275 words 28 Text: 3,592 words 29 References: 48 ABSTRACT 33 Background: Early recognition of dementia would allow patients and their families to receive 34 care earlier in the disease process, potentially improving care management and patient outcomes, 35 yet nearly half of patients with dementia are undiagnosed.
INTRODUCTION
Potential EHR predictors of unrecognized dementia 136 A wide range of potential EHR predictors of unrecognized dementia were considered. 137 Some predictors were informed by our prior work 23 and a priori hypotheses regarding factors that 138 might be associated with increased risk of undiagnosed dementia (such as receiving care for 139 dementia-related symptoms, missing clinic visits and poor medication adherence). Other 140 predictors were based on well-established algorithms for administrative data. 28, 29 The period of 141 assessment for most predictors was the two years preceding the ACT visit. Height, weight and 142 blood pressure were not captured in the EHR until 2003; therefore, we used the most recently 143 recorded value from either the EHR or the ACT visit during the preceding three years to 144 minimize missing data. Predictors were grouped into the broad categories of demographics, 145 diagnoses, vital signs, healthcare utilization and medication-related predictors. In addition, to 146 maximize the clinical utility of the tool, we classified predictors as being more or less easily 147 obtainable in most medical systems. A complete list of predictors considered is included in 148 Supplementary Table S1 . More easily obtainable EHR predictors 151 8 a) Demographics: We considered age, gender, and race/ethnicity as potential demographic 152 predictors. Race/ethnicity was dichotomized as non-Hispanic white versus other because the 153 proportion of ACT participants with nonwhite race/ethnicity is small (10%). 154 b) Diagnoses. We identified comorbid medical conditions using a code list drawn primarily 155 from ICD-9 codes recommended by Elixhauser or Charlson. 28, 29 A total of 31 specific conditions 156 were considered including hypertension, myocardial infarction, congestive heart failure, 157 cerebrovascular disease, diabetes, alcohol dependence/abuse, psychoses, depression, traumatic 158 brain injury, tobacco use disorder, atrial fibrillation and gait abnormality. 159 c) Vital signs. Height, weight and blood pressure were determined based on the most 160 recently recorded EHR value. Height and weight were used to calculate body mass index (BMI, 161 kg/m 2 ), which was classified using standard cut-points: underweight (<18.5), normal (18.5-24.9 databases to identify "no shows" for scheduled clinic visits. 184 b) Medication-related predictors. We examined medication adherence for three categories of 185 commonly prescribed medications (oral hypoglycemic agents, antihypertensive medications and 186 statins). Non-adherence was defined as <80 percent of days covered (PDC), consistent with 187 national quality measures. 31 Individuals who did not take these medications or had ≥80% PDC 188 were classified as adherent. Four variables were created to reflect non-adherence for each class 189 separately as well as overall. to build a prediction model to estimate the probability of unrecognized dementia for each person 195 at each visit. Visits classified as 'recognized dementia' were excluded since our goal was to 196 identify patients with unrecognized dementia to target for further evaluation.
197
The LASSO penalization factor selects predictors by shrinking coefficients for weaker 198 predictors toward zero, excluding predictors with estimated zero coefficients from the final 199 prediction model. Simulation studies suggest that LASSO leads to less overfitting and more 200 accurate prediction models than more traditional methods such as stepwise selection. 33
201
For model development and validation, we randomly divided the data into training (70%) 202 and test (30%) samples. To minimize overfitting, we used the training sample to select the 203 LASSO tuning parameter that minimized the binomial deviance via 10-fold cross validation. 204 We generated the final model by fitting the logistic regression with LASSO to the entire training 205 sample using the selected tuning parameter. We implemented the above procedure using the 
209
Confidence intervals for AUC estimates were calculated via bootstrap with 10,000 replications.
210
Two models were created. We first considered the full set of 64 predictors described in 211 the preceding section. Next, to maximize the potential portability of the model into other 212 healthcare systems, we rebuilt the model after excluding predictors likely to be difficult to obtain 213 in some settings (specifically, variables based on ACS conditions, no shows and medication non-214 adherence).
215
For sensitivity analyses, we explored alternative modeling using other machine learning 216 methods such as ridge regression, decision trees, random forests, gradient boosting, support 217 vector machines, and neural networks. 35 We also estimated another prediction model using all our study period without developing dementia, 4.7% disenrolled from KPWA, and 5.5% were 233 lost to follow-up (e.g., did not return for their biennial visits). At the visit level, 1,015 visits 234 resulted in an ACT dementia diagnosis, of which about half (n=498) were unrecognized in the 235 EHR (overall, 49%; 1996-2000, 54%; 2001-2005: 59%; 2006-2010: 46%; 2011-2015: 38%) . The 236 mean age of participants over the visits was 80 years, and 60% of visits were in female 237 participants. Table 1 shows the prevalence of selected predictors overall and stratified by 238 dementia status at the time of the visit. Data for all predictors considered are included in 239 Supplementary Table S1 . The final coefficients for the restricted and full models are shown in Table 2 . The 241 restricted model included a combination of demographics (older age, male sex); medical 242 diagnoses (e.g., psychoses, diabetes, congestive heart failure, cerebrovascular disease, gait 243 abnormalities); healthcare utilization (e.g., emergency department or speech therapy visits); vital 244 signs (e.g., underweight); and medication-related predictors (e.g., antidepressant fills other than 
249
In the full model, most predictors and coefficient values were similar to those for the 250 restricted model ( Table 2 ). The key differences were that some variables were no longer included 251 (diabetes, lymphoma, or depression diagnoses; home health visits; sedative/hypnotic medication Table 3 shows performance characteristics of the final restricted model when using 263 different predicted risk cut-offs for classifying subjects as having unrecognized dementia at a 264 given visit (see Supplementary Table S3 for full model In this study of more than 16,000 visits between 1995 and 2015 among 4,330 older adults 278 from the ACT study, 24 we found that about half of participants who were diagnosed with incident 279 dementia through ACT appeared to be unrecognized by the healthcare system. The proportion 280 who were unrecognized declined slightly over time but was high in all study years. These 281 findings are consistent with prior studies 2, 5, 17, 36 and suggest that under-recognition of dementia 282 remains a major concern.
283 We also found that information that is readily available in the EHR can be used to detect 284 patients who may have unrecognized dementia with good accuracy. Key predictors included 285 patterns of health care utilization, dementia-related symptoms, and dementia risk factors. We 286 also found that variables such as poor medication adherence and clinic visit 'no shows' were 287 associated with increased risk of unrecognized dementia, although adding these more novel 288 predictors (which may be difficult to extract in some EHRs) did not improve prognostic accuracy 289 compared to a model that only considered more easily extractable predictors. This may be 290 explained by correlations between predictors that enabled substitutions without loss of 291 prognostic performance. Model accuracy was slightly better in the test sample, suggesting that 292 over-fitting is not a concern.
293 We also examined the trade-offs between sensitivity and PPV to understand the potential 294 impact of implementing eRADAR in clinical practice. If the 85 th percentile were set as a 295 threshold for recommending follow-up evaluation (for example, a phone or office visit to assess 296 memory), sensitivity would be 47% and PPV 10%-that is, we would detect nearly half of 297 patients with undiagnosed dementia, and about 1 in 10 people evaluated would have dementia.
298
For context, 12% of screening mammograms are interpreted as abnormal, with 87% sensitivity 299 and 4% PPV (~23 people evaluated with diagnostic mammograms and/or biopsies to detect 1 300 breast cancer). 37 For fecal immunochemical testing (FIT), a recent community-based study 301 found 74% sensitivity and 2% PPV using a 20 mcg/g cut-off (~52 people evaluated via 302 colonoscopy to detect 1 case of colorectal cancer). 38 Screening Indicator 41 is a simple tool designed to identify older adults with an elevated risk of 308 15 developing dementia within 6 years. These tools may be optimal for identifying patients to target 309 for risk reduction interventions, rather than detecting patients with unrecognized dementia, since 310 they focus on predicting future risk.
311
Several other tools have recently been developed that use text-based EHR data to more 312 accurately differentiate between patients with and without dementia. [42] [43] [44] For example, Amra et 313 al. 42 developed an algorithm that uses EHR text words (such as "cognitive impairment," 314 "impaired memory" or "difficulty concentrating") to discriminate between patients with and 315 without dementia. A limitation is that many clinical settings may not have the resources or 316 technical capabilities to extract information from free text fields such as clinic notes. Also, such 317 approaches are likely to identify patients who are already known by clinicians to potentially have 318 dementia. In contrast, our tool is designed to identify patients with dementia who have not yet 319 been recognized by their clinicians.
320
Another limitation of prior studies is that most models were developed to predict 321 diagnosed dementia and have assumed that results would apply to undiagnosed dementia. [43] [44] [45] 
322
However, our prior work suggests that patients with undiagnosed dementia often have values that 323 fall in between patients with diagnosed dementia and those without dementia. 23 Thus, models 324 that are optimized to predict diagnosed dementia may be less accurate for identifying 325 unrecognized dementia cases.
326
This study has several strengths. We examined a large sample that included 16,655 visits 327 among 4,330 patients and nearly 500 cases of unrecognized dementia. In addition, we examined 328 a wide range of potential EHR predictors based on a conceptual model developed a priori. 329 We also acknowledge several limitations. 1) Our definition of unrecognized dementia 330 relied on EHR diagnosis codes and medication fills. It is possible that some clinicians were 331 16 aware of a patient's dementia status but did not code or prescribe medications for it, although our 332 pilot work confirmed that 90% of cases were unrecognized based on detailed chart review. 23 2) 333 Generalizability may be limited given our sample, which was primarily white, well-educated, 334 English speaking, and from one healthcare system in one region of the country. Patterns of 335 healthcare utilization, access to services and medication compliance may differ in those with 336 lower socioeconomic status or education levels, and results may not be readily transported 337 outside the U.S. where practices for screening, diagnosis and coding of dementia may differ. 3)
338
If implemented, the model would not identify all patients with undiagnosed dementia, and those 339 not identified would not be targeted for further evaluation. 4) Some predictors in the final model 340 do not make intuitive sense; for example, solid tumor without metastasis is associated with a 341 lower risk of undiagnosed dementia. These patients may be more likely to receive a diagnosis 342 due to greater interaction with the health care system. We also note that prognostic models can 343 be accurate even when counterintuitive. 5) There are other predictors that we did not consider in 344 this model, such as antipsychotic and anticholinergic medications, non-compliance with other 345 types of medications, laboratory test results, and hospital visits with delirium or intensive care 346 unit stays. We also did not use techniques such as natural language processing to examine 347 clinical note fields. Future studies should determine whether the accuracy of our model is 348 improved by including additional predictors or using alternative techniques. It also would be of 349 great value to validate our model in new databases or through a prospective validation study 350 within a real-world population. 351 We recognize that there are many barriers to dementia diagnosis, 5, 17, 19, 21, 46 and that the 352 idea of applying a tool such as eRADAR to detect cases of unrecognized dementia may raise 353 concerns among some patients or clinicians. For example, one study found that nearly half of 354 patients with positive dementia screens declined further evaluation. 47 Implementing an EHR-355 based tool will require careful design and should incorporate input and guidance from patients, 356 caregivers and clinicians to address barriers and minimize the potential for unintended adverse 357 consequences. It is likely that both clinicians and patients will need enhanced support and 358 resources if more cases of dementia are detected.
359
In summary, we have developed and internally validated eRADAR, a tool that uses 360 readily available EHR data to identify patients who may have unrecognized dementia with good 361 accuracy. Future studies should explore the optimal approach to implementing eRADAR, which 362 could involve applying it at the point of care (e.g. an EHR-based alert that could fire during a 363 clinic visit) or providing risk score information to clinical teams to support proactive outreach to 364 patients outside of scheduled visits. 48 Future studies should assess not only benefits but also 365 potential downstream costs or burdens to the patient, family and healthcare system. 
